霍奇金淋巴瘤 (HL) 是一种罕见的淋巴肿瘤，其中霍奇金/里德-斯坦伯格 (HRS) 细胞与一群非肿瘤性炎症细胞和纤维化混合。细胞周期调节因子和转录因子的表达失调已被证明是 HL 的标志之一。在此背景下，SATB1 和 p16 已被报道为 HL 进展和生存的潜在调节因子。然而，迄今为止，尚无研究评估克罗地亚患者 HL 中 SATB1 和 p16 的表达水平或其预后价值。因此，我们使用标准免疫组织化学研究了石蜡包埋淋巴结活检中 SATB1 和 p16 的表达模式。我们发现 21% 的患者 SATB1 染色呈阳性，而 15% 的患者 p16 染色呈阳性。此外，我们的目的是通过分析总生存期（OS）和无进展生存期（PFS）来了解每种蛋白质的预后价值。 SATB1 与更好的 OS 和 PFS 呈显着正相关，而 p16 表达没有影响。有趣的是，当结合两种研究标志物对患者进行分层时，我们发现根据统计显着性，SATB1 /p16- 组的患者在 HL 中往往具有最佳预后。总之，SATB1 和 p16 可能作为 HL 的诊断和预后标志物有用。

Hodgkin lymphoma (HL) is a rare lymphoid neoplasm in which Hodgkin/Reed-Stenberg (HRS) cells are admixed with a population of non-neoplastic inflammatory cells and fibrosis. Dysregulated expressions of cell cycle regulators and transcription factors have been proven as one of the hallmarks of HL. In that context, SATB1 and p16 have been reported as potential regulators of HL progression and survival. However, to date, no studies have assessed the expression levels of SATB1 and p16 in HL in Croatian patients or their prognostic values. Therefore, we investigated the expression pattern of SATB1 and p16 in paraffin-embedded lymph node biopsies using standard immunohistochemistry. We found that 21% of the patients stained positive for SATB1, while 15% of the patients displayed positive staining for p16. Furthermore, we aimed to understand the prognostic value of each protein through the analysis of the overall survival (OS) and progression-free survival (PFS). SATB1 showed a significantly positive correlation with better OS and PFS, while p16 expression had no impact. Interestingly, when patients were stratified by a combination of the two studied markers, we found that patients in the SATB1+/p16- group tended to have the best prognosis in HL, according to statistical significance. In conclusion, SATB1 and p16 might be potentially useful as diagnostic and prognostic markers for HL.